Home > Publications database > Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer. > print

001     294330
005     20250228163922.0
024 7 _ |a 10.1016/j.trecan.2024.10.006
|2 doi
024 7 _ |a pmid:39448335
|2 pmid
024 7 _ |a 2405-8033
|2 ISSN
024 7 _ |a 2405-8025
|2 ISSN
037 _ _ |a DKFZ-2024-02163
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Suarez-Carmona, Meggy
|0 P:(DE-He78)7eaaf5131f5096c7ff7de12dde4ceca5
|b 0
|e First author
|u dkfz
245 _ _ |a Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.
260 _ _ |a Amsterdam
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1740749145_27535
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D196#LA:D196# / 2024 Dec;10(12):1093-1094 / HI-TRON / SPOTLIGHT
520 _ _ |a Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a MSI
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a dMMR
|2 Other
650 _ 7 |a immune checkpoint inhibition
|2 Other
650 _ 7 |a neoadjuvant therapy
|2 Other
700 1 _ |a Halama, Niels
|0 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601
|b 1
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.trecan.2024.10.006
|g p. S2405803324002255
|0 PERI:(DE-600)2852626-0
|n 12
|p 1093-1094
|t Trends in cancer
|v 10
|y 2024
|x 2405-8033
909 C O |o oai:inrepo02.dkfz.de:294330
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)7eaaf5131f5096c7ff7de12dde4ceca5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 p c |a APC keys set
|0 PC:(DE-HGF)0000
|2 APC
915 p c |a Local Funding
|0 PC:(DE-HGF)0001
|2 APC
915 p c |a DFG OA Publikationskosten
|0 PC:(DE-HGF)0002
|2 APC
915 p c |a DEAL: Elsevier 09/01/2023
|0 PC:(DE-HGF)0125
|2 APC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b TRENDS CANCER : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b TRENDS CANCER : 2022
|d 2023-08-25
920 2 _ |0 I:(DE-He78)D196-20160331
|k D196
|l Translationale Immuntherapie
|x 0
920 1 _ |0 I:(DE-He78)D196-20160331
|k D196
|l Translationale Immuntherapie
|x 0
920 0 _ |0 I:(DE-He78)D196-20160331
|k D196
|l Translationale Immuntherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D196-20160331
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21